# Bruker Corp: Form 10-Q for the period ended Sep 30, 2025

- Company: [Bruker Corp](/companies/brkr.md) (CIK 1109354)
- Form: 10-Q
- Filed: 2025-11-05
- Accepted by EDGAR: Nov 5, 2025, 16:30 ET
- Period: 2025-09-30
- Accession: 0001193125-25-267049
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1109354/000119312525267049/brkr-20250930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1109354/000119312525267049/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2025-07-01 to 2025-09-30 | $860.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2025-01-01 to 2025-09-30 | $2.46bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2025-07-01 to 2025-09-30 | $481.1m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2025-01-01 to 2025-09-30 | $1.33bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2025-07-01 to 2025-09-30 | $379.4m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2025-01-01 to 2025-09-30 | $1.13bn | us-gaap:GrossProfit |
| Research and development | 3 months, 2025-07-01 to 2025-09-30 | $98.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2025-01-01 to 2025-09-30 | $295.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2025-07-01 to 2025-09-30 | $242.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2025-01-01 to 2025-09-30 | $699.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2025-07-01 to 2025-09-30 | −$51.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2025-01-01 to 2025-09-30 | −$8.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2025-07-01 to 2025-09-30 | $20.3m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months, 2025-01-01 to 2025-09-30 | $49.1m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months, 2025-07-01 to 2025-09-30 | −$14.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2025-01-01 to 2025-09-30 | −$8.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2025-07-01 to 2025-09-30 | −$59.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2025-01-01 to 2025-09-30 | −$34.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2025-07-01 to 2025-09-30 | −$0.41 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2025-01-01 to 2025-09-30 | −$0.25 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2025-07-01 to 2025-09-30 | −$0.41 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2025-01-01 to 2025-09-30 | −$0.25 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2025-07-01 to 2025-09-30 | 151,800,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2025-01-01 to 2025-09-30 | 151,700,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2025-01-01 to 2025-09-30 | −$95.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2025-01-01 to 2025-09-30 | $68.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2025-01-01 to 2025-09-30 | $15.3m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2025-01-01 to 2025-09-30 | $10.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2025-09-30 | $293.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-09-30 | $2.35bn | us-gaap:AssetsCurrent |
| Total assets | at 2025-09-30 | $6.43bn | us-gaap:Assets |
| Current liabilities | at 2025-09-30 | $1.27bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2025-09-30 | $1.98bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2025-09-30 | $2.43bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 46,608 characters.

The following discussion of our financial condition and results of operations should be read in conjunction with our interim unaudited condensed consolidated financial statements and the notes to those statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q, and in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2024. The dollar amounts listed in the tables presented in Management’s Discussion and Analysis of Financial Condition and Results of Operations are in millions of U.S. Dollars.

Any statements other than statements of historical fact contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this Quarterly Report on Form 10-Q may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Without limiting the foregoing, the words “believe,” “anticipate,” “plan,” “expect,” “seek,” “may,” “will,” “intend,” “estimate,” “should” and similar expressions are intended to identify forward-looking statements.

Forward-looking statements include, but are not limited to, statements regarding:

- the impact of supply chain challenges on our business and operations, including inventory supply problems, global supply chain challenges, changes to trade policies, financial market volatility and disruption, and other macroeconomic issues, including the duration and impact of the current U.S. government shutdown, the impact of prolonged closures or staffing reductions at governmental agencies resulting from the current U.S. government shutdown effecting our business, and uncertain economic conditions in the United States and abroad;
- our cost savings initiatives;
- our working capital requirements and sufficiency of cash to fund our operations and investment activities;
- our plans to make capital investments;
- the impact of changes to tax and accounting rules, and changes in law, including the One Big Beautiful Bill Act (the “OBBBA”);
- fluctuations in estimates impacting costs related to our self-funded health insurance plan;
- our expectations regarding backlog and revenue;
- our expectations and the impact of our restructuring initiatives or success of our acquisitions;
- the impact of our global IT transformation activities;
- the impact of foreign currency exchange rates and changes in commodity prices; and
- any other statements that address events or developments that the Company intends or believes will or may occur in the future.

Actual results may differ from those referred to in any forward-looking statements due to a number of factors, including, but not limited to, the risks described in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and in this Quarterly Report on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

We can experience quarter-to-quarter fluctuations in our operating results as a result of various factors, some of which are outside our control, such as:

- general economic conditions, including inflation, the threat of recession, financial liquidity, currency volatility or devaluation, supply chain or manufacturing capabilities, uncertain economic conditions in the United States and abroad, and additional tariffs, including those imposed or that may be imposed or changed by the presidential administration in the U.S. and uncertainties relating to the same;
- geopolitical tensions, including those that have or may have impact on our customers, such as the conflict between Russia and Ukraine and related economic sanctions, the conflict in the Middle East and surrounding areas, the possible expansion of such conflicts and potential geopolitical consequences, the ongoing tensions between the United States and China, tariff and trade policy changes, and increasing potential conflict involving countries in Asia that are significant to the Company’s supply chain operations, such as Taiwan and China;
- the impact of potential governmental investigations involving regulatory, marketing, and other business practices, which may result in the commencement of civil and criminal proceedings, fines, penalties, and administrative remedies;
- potential energy shortages in Europe where the Company has significant operations;
- the impacts of climate change and certain weather-related disruptions;
- the timing of governmental stimulus programs and academic research budgets;
- the time it takes between the date customer orders and deposits are received, systems are shipped and accepted by our customers, and full payment is received;
- foreign currency exchange rates;
- the worldwide shortage of semiconductor chips, components, and raw materials, such as copper;
- changes in raw material, component, and logistics costs;
- the time it takes for us to receive critical materials to manufacture our products;
- the time it takes to satisfy local customs requirements and other export/import requirements;
- the time it takes for customers to construct or prepare their facilities for our products;
- the time required to obtain governmental licenses;
- our ability to achieve desired cost savings;
- our ability to identify suitable acquisition targets and successfully integrate and manage acquired business; and
- costs related to acquisitions of technology or businesses.

Several of these factors have in the past affected and may continue to affect the amount and timing of revenue recognized on sales of our products and receipt of related payments, and will likely continue to do so in the future. Accordingly, our operating results in any particular quarter may not necessarily be an indication of any future quarter’s operating performance.

### OVERVIEW

We are a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular, and cellular levels. Our corporate headquarters are located in Billerica, Massachusetts. We maintain major research and development and manufacturing centers in Europe, Asia and North America, and we have commercial offices located throughout the world. Bruker is organized into four reportable segments: the Bruker Scientific Instruments (“BSI”) BioSpin Segment, the BSI CALID Segment, the BSI NANO Segment, and the Bruker Energy & Supercon Technologies (“BEST”) Segment.

### Consolidated Results

The following table presents a summary of our consolidated results as of the three and nine months ended September 30, 2025 and 2024:

| GAAP Financial Measures: | Three Months Ended September 30, 2025 | 2024 | Nine Months Ended September 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| Revenue | $860.5 | $864.4 | $2,459.3 | $2,386.8 |
| Revenue year-on-year Growth Rate | (0.5)% | 17.4% | 3.0% | 11.4% |
| Gross Profit | $379.4 | $418.8 | $1,128.5 | $1,156.2 |
| Gross Profit Margin | 44.1% | 48.4% | 45.9% | 48.4% |
| Operating (Loss) Income | $(51.8) | $68.1 | $(8.1) | $181.0 |
| Operating (Loss) Income Margin | (6.0)% | 7.9% | (0.3)% | 7.6% |
| Net cash (used in) provided by operating activities | $(33.2) | $38.4 | $(95.7) | $61.3 |
| **Non-GAAP Financial Measures (see 'Non-GAAP Measures' below):** |  |  |  |  |
| Non-GAAP Constant-exchange rate (CER) currency revenue | $835.6 | $859.2 | $2,421.4 | $2,390.0 |
| Non-GAAP Constant-exchange rate (CER) currency revenue year-on-year growth rate | (3.4)% | 15.7% | 1.4% | 13.2% |
| Non-GAAP Organic Revenue | $825.8 | $766.1 | $2,312.8 | $2,195.1 |
| Non-GAAP Organic Revenue year-on-year growth rate | (4.5)% | 3.1% | (3.1)% | 4.0% |
| Non-GAAP Gross Profit | $430.9 | $442.2 | $1,229.0 | $1,222.7 |
| Non-GAAP Gross Profit Margin | 50.1% | 51.2% | 50.0% | 51.2% |
| Non-GAAP Operating Income | $105.9 | $129.1 | $279.6 | $340.5 |
| Non-GAAP Operating Income Margin | 12.3% | 14.9% | 11.4% | 14.3% |
| Non-GAAP Free Cash Flow | $(54.1) | $5.8 | $(163.9) | $(17.3) |

Discussion of GAAP financial measures follows in the Results of Operations paragraphs.

### Non-GAAP Financial Measures

### Uses and definitions:

Although our unaudited condensed consolidated financial statements have been prepared in accordance with GAAP, we believe that describing revenue excluding the effects of foreign currency, and expenses excluding costs related to restructuring actions, acquisitions, and related integration expenses, amortization of acquired intangible assets, costs associated with our global information technology, transition initiatives, and other costs (“non-GAAP adjustments”), provides meaningful supplemental information regarding our performance but should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. We rely internally on certain measures that are not calculated according to GAAP. These measures include constant exchange rate (“CER”) currency revenue growth, organic revenue growth, non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP operating income, non-GAAP operating margin, and free cash flow.

Our management believes that these financial measures provide relevant and useful information that is widely used by equity analysts, investors, and competitors in our industry, as well as by our management, in assessing both consolidated and business unit performance and are useful measures to evaluate our continuing business. Additionally, management believes free cash flow is a useful measure to evaluate our business as it indicates the amount of cash generated after additions to property, plant, and equipment which is available for, among other things, investments in our business, acquisitions, share repurchases, dividends, and repayment of debt.

We regularly use these non-GAAP financial measures internally to understand, manage, and evaluate our business results and make operating decisions. We also measure our employees and compensate them, in part, based on such non-GAAP measures and use this information for our planning and forecasting activities. These measures may also be useful to investors in evaluating the underlying operating performance of our business. The presentation of these non-GAAP financial measures is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP, and it may be different from non-GAAP financial measures used by other companies and, therefore, may not be comparable among companies.

We define our non-GAAP financial measures as follows:

- CER currency revenue growth as GAAP revenue excluding the effect of changes in foreign currency translation rates.
- Organic revenue growth as GAAP revenue excluding the effect of changes in foreign currency translation rates and acquisitions.
- Non-GAAP gross profit as GAAP gross profit excluding certain non-GAAP adjustments.
- Non-GAAP gross profit margin as GAAP gross profit margin excluding the impact of certain non-GAAP adjustments.
- Non-GAAP operating income as GAAP operating income excluding non-GAAP adjustments.
- Non-GAAP operating income margin as GAAP operating income margin excluding the impact of non-GAAP adjustments.
- Free cash flow as GAAP net cash provided by operating activities less additions to property, plant, and equipment.

### Reconciliations of GAAP to Non-GAAP financial measures:

#### GAAP revenue to non-GAAP CER currency revenue:

|  | Three Months Ended September 30, 2025 | 2024 | Nine Months Ended September 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| GAAP revenue | $860.5 | $864.4 | $2,459.3 | $2,386.8 |
| Non-GAAP adjustments: |  |  |  |  |
| Effect of changes in foreign currency translation rates | 24.9 | 5.2 | 37.9 | (3.2) |
| **Non-GAAP CER currency revenue** | $835.6 | $859.2 | $2,421.4 | $2,390.0 |
| Non-GAAP CER currency revenue growth rate | (3.4)% | 15.7% | 1.4% | 13.2% |

The non-GAAP CER revenue decline in the three months ended September 30, 2025, compared to the year ago quarter, was driven primarily by slower demand in academic and government research markets for our life science instruments, partially offset by higher revenue from biopharma research and applied markets as well as the current year impact of recent acquisitions. The increase in non-GAAP CER in the nine months ended September 30, 2025, compared to the year ago period, reflects increased revenue from prior year acquisitions offset by reduced revenue from the weakened academic and government research markets and biopharma research.

#### GAAP revenue to non-GAAP Organic revenue:

|  | Three Months Ended September 30, 2025 | 2024 | Nine Months Ended September 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| GAAP revenue | $860.5 | $864.4 | $2,459.3 | $2,386.8 |
| Non-GAAP adjustments: |  |  |  |  |
| Acquisitions and divestitures | 9.8 | 93.1 | 108.6 | 194.9 |
| Effect of changes in foreign currency translation rates | 24.9 | 5.2 | 37.9 | (3.2) |
| **Non-GAAP Organic revenue** | $825.8 | $766.1 | $2,312.8 | $2,195.1 |

The non-GAAP organic revenue decline in the three months and nine months ended September 30, 2025, compared to the year-ago periods, was primarily a result of similar drivers to those described above under *GAAP revenue to non-GAAP CER currency revenue.*

#### GAAP Gross Profit to non-GAAP Gross Profit:

|  | Three Months Ended September 30, 2025 |  | 2024 |  | Nine Months Ended September 30, 2025 |  | 2024 |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Gross profit | $379.4 | 44.1% | $418.8 | 48.4% | $1,128.5 | 45.9% | $1,156.2 | 48.4% |
| Non-GAAP adjustments: |  |  |  |  |  |  |  |  |
| Restructuring costs | 20.2 | 2.3% | 1.2 | 0.1% | 27.2 | 1.1% | 9.8 | 0.4% |
| Acquisition-related costs | 2.0 | 0.2% | 6.8 | 0.8% | 7.1 | 0.3% | 18.5 | 0.8% |
| Purchased intangible amortization | 14.6 | 1.7% | 13.9 | 1.6% | 43.6 | 1.8% | 33.7 | 1.4% |
| Intangible assets impairment charges | 12.6 | 1.5% | — | — | 18.3 | 0.7% | 0.4 | — |
| Other costs | 2.1 | 0.3% | 1.5 | 0.3% | 4.3 | 0.2% | 4.1 | 0.2% |
| Non-GAAP gross profit | $430.9 | 50.1% | $442.2 | 51.2% | $1,229.0 | 50.0% | $1,222.7 | 51.2% |

41

The slight decrease in Non-GAAP gross profit margin in the three and nine months ended September 30, 2025, compared to the year-ago quarter, was driven by decline of revenue primarily as result of slower demand in academic and government research markets, combined with an increase in cost of goods sold due to higher U.S. tariffs and foreign exchange headwinds from a declining U.S. dollar, partially offset by the impact of cost savings initiatives.

#### GAAP Operating income to non-GAAP Operating income:

|  | Three Months Ended September 30, 2025 |  | 2024 |  | Nine Months Ended September 30, 2025 |  | 2024 |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating income | $(51.8) | (6.0)% | $68.1 | 7.9% | $(8.1) | (0.3)% | $181.0 | 7.6% |
| Non-GAAP adjustments: |  |  |  |  |  |  |  |  |
| Restructuring costs | 34.5 | 4.0% | 4.3 | 0.5% | 52.0 | 2.1% | 17.6 | 0.7% |
| Acquisition-related costs | 4.7 | 0.5% | 12.6 | 1.5% | 17.1 | 0.7% | 43.5 | 1.8% |
| Acquisition-related hybrid liability adjustments | (43.7) | (5.1)% | 0.7 | 0.1% | (42.0) | (1.7)% | 2.9 | 0.1% |
| Purchased intangible amortization | 30.3 | 3.5% | 28.8 | 3.3% | 89.1 | 3.6% | 70.1 | 2.9% |
| Acquisition-related litigation charges | 4.1 | 0.5% | 9.0 | 1.0% | 26.7 | 1.1% | 10.5 | 0.5% |
| Goodwill and intangible assets impairment charges | 119.4 | 13.9% | — | — | 126.6 | 5.1% | 0.4 | — |
| Other costs | 8.4 | 1.0% | 5.6 | 0.6% | 18.2 | 0.8% | 14.5 | 0.7% |
| Non-GAAP operating income | $105.9 | 12.3% | $129.1 | 14.9% | $279.6 | 11.4% | $340.5 | 14.3% |

The decrease in our non-GAAP operating margin in the three and nine months ended September 30, 2025, compared to the year-ago periods, was driven primarily by lower non-GAAP gross profit, the impact of foreign currency translation, and the impact of prior period acquisitions, partially offset by costs savings initiatives.

#### GAAP Net operating cash flow to non-GAAP Free cash flow:

|  | Nine Months Ended September 30, 2025 | 2024 |
| --- | ---: | ---: |
| GAAP net cash (used in) provided by operating activities | $(95.7) | $61.3 |
| Less: purchases of property, plant and equipment | (68.2) | (78.6) |
| Free cash flow | $(163.9) | $(17.3) |

For the nine months ended September 30, 2025, our free cash flow decreased by $146.6 million compared to the same period in 2024, primarily due to lower net income and an increase in tax payments in the first nine months of 2025.

### RESULTS OF OPERATIONS

#### Three Months Ended September 30, 2025, compared to the Three Months Ended September 30, 2024

### Consolidated Results

The following table presents our results for the periods reported:

|  | Three Months Ended September 30, 2025 | 2024 | Dollar Change | Percentage Change |
| --- | ---: | ---: | ---: | ---: |
| Product revenue | $691.1 | $709.3 | $(18.2) | (2.6)% |
| Service and other revenue | 169.4 | 155.1 | 14.3 | 9.2% |
| Total revenue | 860.5 | 864.4 | (3.9) | (0.5)% |
| Cost of product revenue | 389.0 | 349.3 | 39.7 | 11.4% |
| Cost of service and other revenue | 92.1 | 96.3 | (4.2) | (4.4)% |
| Total cost of revenue | 481.1 | 445.6 | 35.5 | 8.0% |
| Gross profit | 379.4 | 418.8 | (39.4) | (9.4)% |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative | 242.5 | 229.9 | 12.6 | 5.5% |
| Research and development | 98.3 | 98.1 | 0.2 | 0.2% |
| Goodwill impairment charge | 96.5 | — | 96.5 | 100.0% |
| Other (gains) charges, net | (6.1) | 22.7 | (28.8) | (126.9)% |
| Total operating expenses | 431.2 | 350.7 | 80.5 | 23.0% |
| Operating (loss) income | (51.8) | 68.1 | (119.9) | (176.1)% |
| Interest and other (expense), net | (20.0) | (12.8) | (7.2) | 56.3% |
| (Loss) income before income taxes, equity in income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries | (71.8) | 55.3 | (127.1) | (229.8)% |
| Income tax (benefit) provision | (14.1) | 14.8 | (28.9) | (195.3)% |
| Equity in (losses) of unconsolidated investees, net of tax | (0.8) | (0.2) | (0.6) | 300.0% |
| Consolidated net (loss) income | (58.5) | 40.3 | (98.8) | (245.2)% |
| Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries | 1.1 | (0.6) | 1.7 | (283.3)% |
| Net (loss) income attributable to Bruker Corporation | (59.6) | 40.9 | (100.5) | (245.7)% |
| Dividends on Series A Mandatory Convertible Preferred Stock | 2.8 | — | 2.8 |  |
| Net (loss) income attributable to Bruker Corporation common shareholders | $(62.4) | $40.9 | $(103.3) | (252.6)% |

### Revenue

The following table presents revenue, change in revenue, and revenue growth by reportable segment for the periods reported:

|  | Three Months Ended September 30, 2025 | 2024 | Dollar Change | Percentage Change |
| --- | ---: | ---: | ---: | ---: |
| BSI BioSpin | $208.7 | $233.0 | $(24.3) | (10.4)% |
| BSI CALID | 312.7 | 279.4 | 33.3 | 11.9% |
| BSI Nano | 266.5 | 287.1 | (20.6) | (7.2)% |
| BEST | 73.8 | 68.7 | 5.1 | 7.4% |
| Eliminations (a) | (1.2) | (3.8) | 2.6 |  |
| Total revenue | $860.5 | $864.4 | $(3.9) | (0.5)% |

#### a) Represents product and service revenue between reportable segments.

Revenue decreases for the three months ended September 30, 2025, compared to the year ago quarter, were primarily attributable to the BSI BioSpin and BSI Nano Segments with the decline primarily driven by weaker demand in the academic and government research and biopharma markets for life science instruments. This decrease was partially offset by a year-on-year increase in revenue in the BSI CALID Segment, which was primarily due to improvement in our molecular diagnostics business and from ELITech Group acquisition in the second quarter of 2025.

Geographically during the three months ended September 30, 2025, compared to the same period in 2024, our North American revenue decreased 4.8% and European revenue increased by 7.8%, while Asia Pacific revenue decreased by 3.8%.

### Gross Profit

The following table presents gross profit and gross profit margins by reportable segment for the periods reported:

|  | Three Months Ended September 30, 2025 Gross Profit | Percentage of Segment Revenue | 2024 Gross Profit | Percentage of Segment Revenue |
| --- | ---: | ---: | ---: | ---: |
| BSI BioSpin | $90.4 | 43.3% | $115.9 | 49.7% |
| BSI CALID | 159.0 | 50.8% | 147.1 | 52.6% |
| BSI Nano | 118.4 | 44.4% | 142.0 | 49.5% |
| BEST | 11.6 | 15.7% | 13.8 | 20.1% |
| Total gross profit | $379.4 | 44.1% | $418.8 | 48.4% |

The decrease in gross profit and gross profit margin, compared to the prior year quarter, were driven primarily by increased restructuring costs and impairment charges as well as the impact of U.S. tariffs and foreign exchange headwinds from a declining U.S. dollar.

### Selling, General and Administrative

Our selling, general and administrative expenses for the three months ended September 30, 2025, increased to 28.2% of total revenue, from 26.6% of total revenue for the comparable period in 2024. The increase as a percentage of revenue was mainly a result of foreign exchange headwinds from a declining U.S. dollar and increased spending associated with prior year acquisitions.

### Research and Development

Our research and development expenses for the three months ended September 30, 2025, represented 11.4% of total revenue which is comparable to 11.3% for the same period in 2024.

### Goodwill Impairment Charge

We test goodwill for impairment annually as of October 1 or more frequently if impairment indicators arise at the reporting unit level, which is the operating segment or one level below an operating segment. Due to the current macroeconomic conditions and uncertainties related to the future forecasts, the Company concluded that it was more likely than not that the fair value of one or more of the Company’s reporting units was less than their carrying amount. As a result, the Company performed a quantitative impairment test for impairment in certain reporting units as of October 1, 2025 as these reporting units had the highest uncertainty related to quantity and timing of future cash flows. As these conditions existed as of the balance sheet date, any impairment charges are recognized in the unaudited condensed consolidated statement of operations for the period ended September 30, 2025. The results of the valuation indicated that the carrying amount of the Bruker Spatial Biology (“BSB”) reporting unit within the Company’s BSI NANO Segment and Automation (“AUT”) reporting unit within the Company’s BSI BioSpin Segment exceeded their fair value. As a result, during the three and nine months ended September 30, 2025, the Company recorded a goodwill impairment charge of $96.5 million on the unaudited condensed consolidated statements of operations, which represented the amount by which the carrying value of the Bruker Spatial Biology reporting unit and Automation reporting unit exceeded the respective reporting unit’s fair value.

While we will continue to monitor these circumstances, such uncertainties including the current macroeconomic conditions and the timing and quantity of future cash flows may impact the carrying value of our reporting units. If there are any factors that drive changes to key assumptions in our valuation inputs and if the fair value of any of our reporting units declines below the carrying value in the future, additional goodwill impairment charges may be incurred. Refer to *Note 5 Goodwill and Intangible Assets* for further information on our goodwill impairment.

### Other Charges, Net

Other charges, net for the three months ended September 30, 2025, increased to a gain of $6.1 million compared to charges of $22.7 million for the three months ended September 30, 2024. The year over year increase was primarily attributed to an adjustment to the hybrid liability related to certain other majority owned acquisitions as described in *Note 19, Hybrid Instrument Liabilities,* offset by higher restructuring and impairment charges related primarily to restructuring programs as described in *Note 10, Restructuring* as well as impairments of long-lived assets as described in *Note 5 Goodwill and Intangible assets.* Refer to *Note 9, Other Charges, net* for more details on our other charges, net costs.

### Operating Income

The following table presents operating income and operating margins on revenue by reportable segment for the periods reported:

|  | Three Months Ended September 30, 2025 Operating (loss) Income | Percentage of Segment Revenue | 2024 Operating (loss) Income | Percentage of Segment Revenue |
| --- | ---: | ---: | ---: | ---: |
| BSI BioSpin | $8.5 | 4.1% | $48.9 | 21.0% |
| BSI CALID | 47.4 | 15.2% | 37.0 | 13.2% |
| BSI Nano | (72.2) | (27.1)% | 2.6 | 0.9% |
| BEST | 4.6 | 6.2% | 7.7 | 11.2% |
| Corporate, eliminations and other (a) | (40.1) |  | (28.1) |  |
| Total operating (loss) income | $(51.8) | (6.0)% | $68.1 | 7.9% |

*a) Represents corporate costs and eliminations not allocated to the reportable segments.*

In August 2025, we announced a cost savings initiative aimed at reducing annual costs by approximately $100 million to $120 million in 2026, which we intend to have a positive impact on operating income and operating margin. The planned reductions affect all parts of our business including supply chain, manufacturing, commercial operations, administrative functions and research and development.

### Interest and Other Income (Expense), Net

The increase in interest and other income (expense), net for the three months ended September 30, 2025, as compared to the same period in 2024 was primarily due to the impairment costs on certain of our minority investments recognized in the current quarter partially offset by the income on settlement of interest rate swap agreements. Refer to *Note 11, Interest and Other Income (Expense), net* for more details on our interest and other income (expense), net.

### Income Tax Provision

The effective tax rate for the three months ended September 30, 2025 and 2024 were 19.6% and 26.8%, respectively. The decrease in the Company's effective tax rate was primarily due to changes in jurisdictional mix and net favorable discrete adjustments related to the tax impact of the impairment of goodwill, return to provision adjustments, and release of uncertain tax positions.

The OECD introduced its Pillar 2, which provides guidance for a global minimum tax. Various countries have either enacted or are in the process of enacting legislation to implement this framework. Our income tax provision for the three months ended September 30, 2025, reflects currently enacted legislation and guidance related to the model rules. This enacted legislation and guidance had an impact on our income tax provision, resulting in an increase to our adjusted effective tax rate of 1.3% for the three months ended September 30, 2025. We continue to monitor the countries in which it operates as they enact legislation implementing Pillar 2.

### RESULTS OF OPERATIONS

#### Nine Months Ended September 30, 2025, compared to the Nine Months Ended September 30, 2024

### Consolidated Results

The following table presents our results for the periods reports:

|  | Nine Months Ended September 30, 2025 | 2024 | Dollar Change | Percentage Change |
| --- | ---: | ---: | ---: | ---: |
| Product revenue | $1,969.1 | $1,950.6 | $18.5 | 0.9% |
| Service and other revenue | 490.2 | 436.2 | 54.0 | 12.4% |
| Total revenue | 2,459.3 | 2,386.8 | 72.5 | 3.0% |
| Cost of product revenue | 1,057.4 | 967.0 | 90.4 | 9.3% |
| Cost of service and other revenue | 273.4 | 263.6 | 9.8 | 3.7% |
| Total cost of revenue | 1,330.8 | 1,230.6 | 100.2 | 8.1% |
| Gross profit | 1,128.5 | 1,156.2 | (27.7) | (2.4)% |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative | 699.3 | 646.5 | 52.8 | 8.2% |
| Research and development | 295.6 | 272.1 | 23.5 | 8.6% |
| Goodwill impairment charge | 96.5 | — | 96.5 | 100.0% |
| Other (gains) charges, net | 45.2 | 56.6 | (11.4) | (20.1)% |
| Total operating expenses | 1,136.6 | 975.2 | 161.4 | 16.6% |
| Operating (loss) income | (8.1) | 181.0 | (189.1) | (104.5)% |
| Interest and other (expense), net | (38.1) | (30.2) | (7.9) | 26.2% |
| (Loss) income before income taxes, equity in income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries | (46.2) | 150.8 | (197.0) | (130.6)% |
| Income tax (benefit) provision | (8.5) | 50.7 | (59.2) | (116.8)% |
| Equity in income (losses) of unconsolidated investees, net of tax | 0.2 | (0.2) | 0.4 | (200.0)% |
| Consolidated net (loss) income | (37.5) | 99.9 | (137.4) | (137.5)% |
| Net (loss) income attributable to noncontrolling interests in consolidated subsidiaries | (2.9) | 0.5 | (3.4) | (680.0)% |
| Net (loss) income attributable to Bruker Corporation | (34.6) | 99.4 | (134.0) | (134.8)% |
| Dividends on Series A Mandatory Convertible Preferred Stock | 2.8 | — | 2.8 |  |
| Net (loss) income attributable to Bruker Corporation common shareholders | $(37.4) | $99.4 | $(136.8) | (137.6)% |

### Revenue

The following table presents revenue, change in revenue, and revenue growth by reportable segment for the periods reported:

|  | Nine Months Ended September 30, 2025 | 2024 | Dollar Change | Percentage Change |
| --- | ---: | ---: | ---: | ---: |
| BSI BioSpin | $611.8 | $633.3 | $(21.5) | -3.4% |
| BSI CALID | 878.6 | 772.9 | 105.7 | 13.7% |
| BSI Nano | 775.2 | 780.0 | (4.8) | -0.6% |
| BEST | 199.4 | 210.9 | (11.5) | (5.5)% |
| Eliminations (a) | (5.7) | (10.3) | 4.6 |  |
| Total revenue | $2,459.3 | $2,386.8 | $72.5 | 3.0% |

#### a) Represents product and service revenue between reportable segments.

Revenue increases in the nine months ended September 30, 2025, compared to the year ago quarter, were driven mostly by ELITechGroup partially offset by organic revenue decline. The BSI CALID Segment increase in revenue was driven by increased volumes from the Microbiology & Infection Diagnostics division, with increased activity in both the MALDI Biotyper and the ELITech molecular diagnostics businesses, which was acquired in the second quarter of 2024. BSI Nano Segment revenue remained flat year over year. BSI BioSpin decrease in revenue was primarily driven by the current period including no sales of GHz-class NMR systems, compared to two in the comparative period, and weaker demand in the academic and government research and biopharma markets. The BEST revenue decrease was driven mainly by a softness in the clinical MRI market, as well as a strong prior-year comparison for the Research Instruments business.

Geographically, in the nine months ended September 30, 2025, our North American revenue decreased 1.8%, Asia Pacific revenue increased by 2.2%, and European revenue increased by 7.4% compared to the same period in 2024, driven primarily by tailwinds from prior year acquisitions and foreign exchange impacts from a declining U.S. dollar.

### Gross Profit

The following table presents gross profit and gross profit margins by reportable segment for the periods reported:

|  | Nine Months Ended September 30, 2025 Gross Profit | Percentage of Segment Revenue | 2024 Gross Profit | Percentage of Segment Revenue |
| --- | ---: | ---: | ---: | ---: |
| BSI BioSpin | $267.5 | 43.7% | $310.6 | 49.0% |
| BSI CALID | 457.6 | 52.1% | 419.9 | 54.3% |
| BSI Nano | 365.8 | 47.2% | 379.4 | 48.6% |
| BEST | 37.6 | 18.9% | 46.3 | 22.0% |
| Total gross profit | $1,128.5 | 45.9% | $1,156.2 | 48.4% |

The decrease in gross profit compared to the prior year was driven primarily by the impact of the ELITechGroup and NanoString acquisitions that occurred in 2024 offset by associated business combination amortization expenses, combined with increased restructuring costs and impairment charges as well as the impact of U.S. tariffs and foreign exchange headwinds from a declining U.S. dollar.

### Selling, General and Administrative

Our selling, general and administrative expenses for the nine months ended September 30, 2025, increased to 28.4% of total revenue, from 27.1% of total revenue for the comparable period in 2024. The increase as a percentage of revenue compared to the same period in 2024, was primarily a result of increased costs associated with prior year acquisitions.

### Research and Development

Our research and development expenses for the nine months ended September 30, 2025, increased to 12.0% of total revenue from 11.4% of total revenue for the comparable period in 2024. The increase as a percentage of revenue compared to the same period in 2024, was primarily a result of increased costs associated with prior year acquisitions.

### Goodwill Impairment Charge

During the nine months ended September 30, 2025, the Company recorded a goodwill impairment charge of $96.5 million on the unaudited condensed consolidated statements of operations, which represented the amount by which the carrying value of the Bruker Spatial Biology reporting unit within the Company’s BSI NANO Segment and Automation reporting unit within the Company’s BSI BioSpin Segment exceeded the respective reporting unit’s fair value. Refer to *Results of Operations three months ended September 30, 2025, compared to the three months ended September 30, 2024 above and Note 5 Goodwill and Intangible Assets* for further information on our goodwill impairment.

### Other Charges, Net

Other charges, net for the nine months ended September 30, 2025, decreased to $45.2 million compared to $56.6 million for the comparable period in 2024. The year over year decrease was primarily due to an adjustment to the hybrid liability related to certain other majority owned acquisitions as described in *Note 19, Hybrid Instrument Liabilities and* a decrease in acquisition-related expenses due to fewer acquisitions closed in the current year compared to 2024, offset by increased restructuring and impairment charges related primarily to restructuring programs as described in *Note 10, Restructuring* as well as impairments of long-lived assets as described in *Note 5 Goodwill and Intangible Assets.* Refer to *Note 9, Other Charges, net* for more details on our other charges, net costs.

### Operating Income

The following table presents operating income and operating margins on revenue by reportable segment for the periods reported:

|  | Nine Months Ended September 30, 2025 Operating Income (Loss) | Percentage of Segment Revenue | 2024 Operating Income (Loss) | Percentage of Segment Revenue |
| --- | ---: | ---: | ---: | ---: |
| BSI BioSpin | $50.2 | 8.2% | $117.4 | 18.5% |
| BSI CALID | 113.8 | 13.0% | 113.6 | 14.7% |
| BSI Nano | (92.6) | (11.9)% | 9.8 | 1.3% |
| BEST | 18.7 | 9.4% | 26.3 | 12.5% |
| Corporate, eliminations and other (a) | (98.2) |  | (86.1) |  |
| Total operating (loss) income | $(8.1) | (0.3)% | $181.0 | 7.6% |

*a) Represents corporate costs and eliminations not allocated to the reportable segments.*

In August 2025, we announced a cost savings initiative aimed at reducing annual costs by approximately $100 million to $120 million in 2026, which we intend to have a positive impact on operating income and operating margin. The planned reductions affect all parts of our business including supply chain, manufacturing, commercial operations, administrative functions and research and development.

### Interest and Other Income (Expense), Net

The increase in interest and other income (expense), net in the nine months ended September 30, 2025, compared to the same period in 2024, was primarily due to higher interest expense and lower foreign exchange differences on the revaluation of monetary items, partially offset by the income on settlement of interest rate swap agreements. Refer to *Note 11, Interest and Other Income (Expense), net* for more details on our interest and other income (expense), net.

### Income Tax Provision

The effective tax rates for the nine months ended September 30, 2025, and 2024 were 18.4% and 33.6%, respectively. The decrease in the Company's effective tax rate was primarily due to a change in jurisdictional mix, and net favorable discrete adjustments related to the tax impact of the impairment of goodwill, return to provision adjustments and release of uncertain tax positions.

The OECD introduced its Pillar 2, which provides guidance for a global minimum tax. Various countries have either enacted or are in the process of enacting legislation to implement this framework. Our income tax provision for the nine months ended September 30, 2025, reflects currently enacted legislation and guidance related to the model rules. This enacted legislation and guidance had an impact on our income tax provision, resulting in an increase to our adjusted effective tax rate of 3.0% for the nine months ended September 30, 2025. We continue to monitor the countries in which it operates as they enact legislation implementing Pillar 2.

### LIQUIDITY AND CAPITAL RESOURCES

### Cash flows

We anticipate that our existing cash and credit facilities will be sufficient to support our operating and investing needs for at least the next twelve months. Our future cash requirements could be affected by acquisitions that we may complete, or the payment of common and preferred dividends in the future. Historically, we have used the liquidity generated from cash flow from operations, debt financings, and issuances of common and preferred stock to finance our growth and operating needs. In the future, there are no assurances that we will continue to generate cash flow from operations, that additional financing alternatives will be available to us, if required, or, if available, will be obtained on terms favorable to us.

We aggregate all bank accounts that are subject to our notional cash pooling arrangement into a single balance on our consolidated balance sheets. Our notional cash pooling arrangement is managed by a third-party financial institution and as of September 30, 2025, it was in a positive position. The cash and cash equivalent balance held outside of the United States in our foreign subsidiaries was primarily located in the Netherlands, Switzerland, and Hong Kong.

The following table presents our cash flows from operating activities, investing activities, and financing activities for the periods reported:

|  | Nine Months Ended September 30, 2025 | 2024 |
| --- | ---: | ---: |
| Net cash (used in) provided by operating activities | $(95.7) | $61.3 |
| Net cash used in investing activities | (141.0) | (1,696.7) |
| Net cash provided by financing activities | 302.7 | 1,304.8 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 44.6 | (9.3) |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $110.6 | $(339.9) |

Net cash used in operating activities during the nine months ended September 30, 2025, resulted primarily from consolidated net income adjusted for non-cash items of $173.3 million being offset from outflows related to changes in operating assets and liabilities, net of acquisitions of $269.0 million. Net cash provided by operating activities during the nine months ended September 30, 2024, resulted primarily from consolidated net income adjusted for non-cash items of $230.5 million, partially offset by a change in operating assets and liabilities, net of acquisitions of $169.2 million.

The decrease in consolidated net income adjusted for non-cash items was primarily driven by the non-cash impairment charges related to goodwill and intangible assets primarily in our BSI BioSpin and BSI NANO segments, write-downs related to a series of smaller minority investments offset by gains attributable to reversals related to certain performance driven liabilities and lower income as a result of increased costs related to recent acquisitions combined with negative impact of new global trade tariffs. The change in operating assets and liabilities, net of acquisitions increased primarily due to timing of income taxes payable and decreased accrued compensation costs as result of cost saving initiatives, offset by increased customer advances and strategic inventory management to handle supply chain challenges.

Net cash used in investing activities during the nine months ended September 30, 2025, resulted primarily from cash paid for acquisitions of $69.7 million, purchases of property, plant and equipment of $68.2 million, and minority investments of $6.6 million. Net cash used in investing activities during the nine months ended September 30, 2024, resulted primarily from cash paid for acquisitions of $1,576.7 million, purchases of property, plant and equipment of $78.6 million, and minority investments of $46.0 million.

Net cash provided by financing activities during the nine months ended September 30, 2025, was primarily from net proceeds from the issuance of Series A Mandatory Convertible Preferred Stock, net of issuance costs of $669.5 million, offset by net repayment of our revolving line of credit of $28.3 million, repayments of long-term debt of $321.3 million, the payment of dividends to common shareholders of $15.3 million, and cash paid for purchases of common stock under our repurchase program of $10.0 million. Net cash provided by financing activities during the nine months ended September 30, 2024, was primarily from proceeds from long-term debt of $972.5 million, proceeds from our public offering of common stock of $403.0 million, and net proceeds from our revolving line of credit of $84.8 million, offset by the repayment of our 2012 Note Purchase Agreement of $100.0 million and the payment of dividends to common shareholders of $22.6 million.

### Issuance of Mandatory Convertible Preferred Stock

On September 8, 2025, we issued 2,760,000 shares, or $690 million aggregate liquidation preference, of our 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share, (including 360,000 shares, or $90,000,000 aggregate liquidation preference, of Mandatory Convertible Preferred Stock issued upon exercise by the underwriters of over-allotment option in full) pursuant to a previously announced underwritten public offering. Dividends on the Mandatory Convertible Preferred Stock will be payable on a cumulative basis when, as and if declared by our Board of Directors, at an annual rate of 6.375% on the liquidation preference of $250 per share. If declared, these dividends will be paid in cash, or, subject to certain limitations, in shares of our common stock or, subject to certain limitations, in a combination of cash and shares of our common stock, at our election, on March 1, June 1, September 1 and December 1 of each year, commencing on December 1, 2025, and ending on, and including, September 1, 2028. We used the proceeds from this issuance to repay (i) our term loan due December 2026 in full, (ii) outstanding borrowings under our 2024 amended and restated revolving credit agreement in full, and (iii) a portion of our term loan due March 2027. Refer to

*Note 21, Shareholder's Equity*, in the Notes to our Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for more information on our mandatory convertible preferred stock.

### Credit Facilities

As of September 30, 2025, we have total outstanding debt of $2.0 billion and a revolving credit facility that provides for up to $900.0 million of backup liquidity to finance working capital needs, refinance or reduce existing indebtedness, and for general corporate use. In addition, the facility provides for an uncommitted incremental facility whereby, under certain circumstances, we may, at our option, increase the amount of the revolving facility or incur term loans in an aggregate amount not to exceed $400 million. As of September 30, 2025, we were in compliance with all covenants of our debt agreements.

For a summary of the fair and carrying values of our outstanding debt as of September 30, 2025, and December 31, 2024, refer to *Note 15, Debt and Note 16, Fair Value of Financial Instruments* to our unaudited condensed consolidated financial statements included in this report. For additional information on our outstanding debt and credit facility refer to, *Note 21, Debt*, to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024.

### Incentive Compensation Plan

In May 2025, the 2026 Plan was approved by our common shareholders. The 2026 Plan will be effective as of the Effective Date, which will be the date immediately following the date on which the Prior Plan expires. No additional awards will be granted under the Prior Plan on or after the Effective Date. The 2026 Plan provides for the issuance of up to 12,000,000 shares of our common stock. The 2026 Plan will be administered by the Compensation Committee of the Board or another Committee, and provides for grants of awards to non-employee directors, employees, and certain of our key advisors in the form of nonqualified and incentive options, stock awards, stock units, stock appreciation rights, cash-based awards, and other awards. The Committee has the authority to determine which employees will receive awards, the amount of any awards, and other terms and conditions of such awards. The 2026 Plan will terminate on May 28, 2035, unless terminated earlier pursuant to its terms.

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

There have been no material changes to our critical accounting policies and estimates since December 31, 2024. Refer to our Annual Report on Form 10-K for the year ended December 31, 2024 for a discussion of our critical accounting policies.

### RECENT ACCOUNTING PRONOUNCEMENTS

Information regarding recent accounting standard changes and developments is incorporated by reference from Part I, Item 1, Unaudited Condensed Consolidated Financial Statements, of this document and should be considered an integral part of this Item 2. Refer to *Note 2, Recent Accounting Pronouncements* in the Notes to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for recently adopted and issued accounting standards.

## Market risk

As filed, 303 characters.

Information concerning market risk is contained in Item 7A “Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2024. As of September 30, 2025, there were no material changes in our exposure to market risk from December 31, 2024.

## Controls and procedures

As filed, 1,478 characters.

We have established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)) that are designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer) by others within our organization. Under the supervision and with the participation of our management, including our Chief Executive Officer, and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of September 30, 2025. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2025.

Management concluded that the unaudited condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q fairly state, in all material respects, our financial condition, results of operations, and cash flows for the periods presented in conformity with GAAP.

### Changes in Internal Controls over Financial Reporting

There have been no changes in our internal control over financial reporting during the three months ended September 30, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed Nov 5, 2025.
Source: SEC EDGAR, the filing index for accession 0001193125-25-267049. Last ingested by Listed: Nov 5, 2026, 16:58 ET. No prices; not investment advice.
